anurajms/meta_analysis huggingface dataset:
MESH terms:
Long‐term antibiotics for preventing recurrent urinary tract infection in children
1. Anti-Infective Agents, Urinary [*therapeutic use]; 2. Antibiotic Prophylaxis; 3. Drug Therapy, Combination; 4. Randomized Controlled Trials as Topic; 5. Recurrence; 6. Secondary Prevention; 7. Urinary Tract Infections [drug therapy, *prevention & control]; 8. Vesico-Ureteral Reflux [prevention & control];
MESH terms:
Constraint‐induced movement therapy in children with unilateral cerebral palsy
1. *Physical Therapy Modalities; 2. Cerebral Palsy [*therapy]; 3. Immobilization [methods]; 4. Movement; 5. Quality of Life; 6. Randomized Controlled Trials as Topic; 7. Treatment Outcome;
MESH terms:
Supplemental perioperative intravenous crystalloids for postoperative nausea and vomiting
1. Administration, Intravenous; 2. Anesthesia, General [*adverse effects]; 3. Crystalloid Solutions [administration & dosage, *therapeutic use]; 4. Postoperative Nausea and Vomiting [chemically induced, epidemiology, *prevention & control]; 5. Randomized Controlled Trials as Topic; 6. Time Factors;
MESH terms:
Family‐based prevention programmes for alcohol use in young people
1. *Family Health; 2. *Family Therapy [methods]; 3. *Program Evaluation; 4. Alcohol Drinking [epidemiology, *prevention & control]; 5. Prevalence; 6. Randomized Controlled Trials as Topic;
MESH terms:
Multiple‐micronutrient supplementation for women during pregnancy
1. *Dietary Supplements; 2. Drug Interactions; 3. Folic Acid [*administration & dosage]; 4. Infant, Small for Gestational Age; 5. Iron, Dietary [*administration & dosage]; 6. Micronutrients [*administration & dosage, adverse effects, deficiency]; 7. Perinatal Mortality; 8. Pregnancy Complications [*therapy]; 9. Pregnancy Outcome; 10. Premature Birth [epidemiology]; 11. Randomized Controlled Trials as Topic;
MESH terms:
Probiotics to prevent infantile colic
1. Bifidobacterium; 2. Breast Feeding; 3. Colic [epidemiology, microbiology, *prevention & control]; 4. Crying; 5. Gastrointestinal Microbiome; 6. Prebiotics [microbiology]; 7. Probiotics [adverse effects, *therapeutic use]; 8. Randomized Controlled Trials as Topic; 9. Time Factors;
MESH terms:
Dental cavity liners for Class I and Class II resin‐based composite restorations
1. *Composite Resins; 2. Dental Caries [classification, surgery]; 3. Dental Cavity Lining [*instrumentation]; 4. Dental Restoration Failure [statistics & numerical data]; 5. *Dental Restoration, Permanent [adverse effects, classification]; 6. Dentin Sensitivity [epidemiology, etiology, *prevention & control]; 7. Pain, Postoperative [*prevention & control]; 8. Randomized Controlled Trials as Topic; 9. *Thermal Conductivity;
MESH terms:
Fluoride toothpastes of different concentrations for preventing dental caries
1. Cariostatic Agents [administration & dosage, *therapeutic use]; 2. DMF Index; 3. Dental Caries [*prevention & control]; 4. Dentition, Permanent; 5. Fluorides [administration & dosage, *therapeutic use]; 6. Network Meta‐Analysis; 7. Randomized Controlled Trials as Topic; 8. Tooth, Deciduous; 9. Toothpastes [chemistry, *therapeutic use];
MESH terms:
Physical exercise training for type 3 spinal muscular atrophy
1. *Exercise; 2. *Resistance Training; 3. Muscle Strength; 4. Oxygen Consumption; 5. Spinal Muscular Atrophies of Childhood [*rehabilitation]; 6. Walk Test;
MESH terms:
The use of ultrasound guidance for perioperative neuraxial and peripheral nerve blocks in children
1. *Ultrasonography, Interventional; 2. Nerve Block [adverse effects, *methods]; 3. Perioperative Care [methods]; 4. Peripheral Nervous System; 5. Randomized Controlled Trials as Topic; 6. Surgical Procedures, Operative; 7. Time Factors;
MESH terms:
Positive end‐expiratory pressure for preterm infants requiring conventional mechanical ventilation for respiratory distress syndrome or bronchopulmonary dysplasia
1. Bronchopulmonary Dysplasia [*therapy]; 2. Infant, Premature; 3. Positive‐Pressure Respiration [adverse effects, *methods, standards]; 4. Pulmonary Gas Exchange; 5. Randomized Controlled Trials as Topic; 6. Respiration, Artificial [adverse effects]; 7. Respiratory Distress Syndrome, Newborn [mortality, *therapy];
MESH terms:
Iodine supplementation for the prevention of mortality and adverse neurodevelopmental outcomes in preterm infants
1. *Dietary Supplements; 2. Developmental Disabilities [etiology, *prevention & control]; 3. Enteral Nutrition; 4. Infant Mortality; 5. Infant, Extremely Premature; 6. Infant, Premature; 7. Iodine [*administration & dosage, *deficiency]; 8. Parenteral Nutrition; 9. Randomized Controlled Trials as Topic;
MESH terms:
Parenteral versus oral iron therapy for adults and children with chronic kidney disease
1. Administration, Oral; 2. Anemia, Iron-Deficiency [blood, *therapy]; 3. Blood Transfusion [statistics & numerical data]; 4. Cause of Death; 5. Ferritins [blood]; 6. Hemoglobin A [metabolism]; 7. Injections, Intravenous; 8. Iron Compounds [*administration & dosage, adverse effects]; 9. Kidney Failure, Chronic [blood, *complications]; 10. Randomized Controlled Trials as Topic; 11. Transferrin [metabolism];
MESH terms:
Education of family members to support weaning to solids and nutrition in infants born preterm
1. *Family; 2. *Food; 3. *Infant, Premature; 4. *Weaning; 5. Infant Nutritional Physiological Phenomena;
MESH terms:
Interventions for primary vesicoureteric reflux
1. Acrylic Resins [therapeutic use]; 2. Anti‐Bacterial Agents [therapeutic use]; 3. Antibiotic Prophylaxis; 4. Collagen [therapeutic use]; 5. Dextrans [therapeutic use]; 6. Dimethylpolysiloxanes [therapeutic use]; 7. Fever [etiology, prevention & control]; 8. Hyaluronic Acid [therapeutic use]; 9. Kidney [abnormalities]; 10. Probiotics [therapeutic use]; 11. Randomized Controlled Trials as Topic; 12. Replantation; 13. Ureter [surgery]; 14. Urinary Tract Infections [complications, *prevention & control]; 15. Vesico‐Ureteral Reflux [complications, *therapy];
MESH terms:
Antibiotic treatment for newborns with congenital syphilis
1. Anti‐Bacterial Agents [*therapeutic use]; 2. Infant Mortality; 3. Penicillin G Benzathine [*therapeutic use]; 4. Penicillin G Procaine [*therapeutic use]; 5. Randomized Controlled Trials as Topic; 6. Syphilis, Congenital [*drug therapy];
MESH terms:
Dietary interventions for induction and maintenance of remission in inflammatory bowel disease
1. Calcium, Dietary [therapeutic use]; 2. Cattle; 3. Colitis, Ulcerative [*diet therapy]; 4. Crohn Disease [*diet therapy]; 5. Dietary Carbohydrates [therapeutic use]; 6. Dietary Fiber [therapeutic use]; 7. Food, Organic; 8. Meat; 9. Quality of Life; 10. Randomized Controlled Trials as Topic; 11. Recurrence; 12. Remission Induction;
MESH terms:
Needle aspiration versus intercostal tube drainage for pneumothorax in the newborn
1. *Chest Tubes [statistics & numerical data]; 2. *Needles; 3. Device Removal; 4. Hemorrhage [etiology]; 5. Hospital Mortality; 6. Pneumothorax [mortality, *therapy]; 7. Randomized Controlled Trials as Topic; 8. Risk; 9. Suction [instrumentation, methods, mortality]; 10. Thoracentesis [instrumentation, *methods, mortality]; 11. Thoracostomy [adverse effects, methods];
MESH terms:
Intermittent iron supplementation for reducing anaemia and its associated impairments in adolescent and adult menstruating women
1. Administration, Oral; 2. Anemia, Iron-Deficiency [*prevention & control]; 3. *Dietary Supplements; 4. Drug Administration Schedule; 5. Ferritins [adverse effects, blood]; 6. Ferrous Compounds [administration & dosage]; 7. Iron Deficiencies; 8. Iron, Dietary [*administration & dosage]; 9. *Menstruation; 10. Micronutrients [administration & dosage]; 11. Randomized Controlled Trials as Topic;
MESH terms:
Phosphodiesterase 5 inhibitors for pulmonary hypertension
1. Endothelin Receptor Antagonists [therapeutic use]; 2. Hypertension, Pulmonary [*drug therapy, etiology, mortality]; 3. Numbers Needed To Treat; 4. Phosphodiesterase 5 Inhibitors [adverse effects, *therapeutic use]; 5. Placebos [therapeutic use]; 6. Quality of Life; 7. Randomized Controlled Trials as Topic; 8. Walk Test;
MESH terms:
Pharmacotherapies for cannabis dependence
1. Acetylcysteine [adverse effects, therapeutic use]; 2. Anticonvulsants [adverse effects, therapeutic use]; 3. Antidepressive Agents [adverse effects, therapeutic use]; 4. Buspirone [adverse effects, therapeutic use]; 5. Dronabinol [adverse effects, therapeutic use]; 6. Marijuana Abuse [*drug therapy]; 7. Randomized Controlled Trials as Topic; 8. Serotonin Receptor Agonists [adverse effects, therapeutic use];
MESH terms:
School‐based self‐management interventions for asthma in children and adolescents: a mixed methods systematic review
1. *School Health Services; 2. Absenteeism; 3. Anti‐Asthmatic Agents [therapeutic use]; 4. Asthma [*therapy]; 5. Disease Progression; 6. Emergency Service, Hospital [statistics & numerical data]; 7. Evaluation Studies as Topic; 8. Health Services Needs and Demand [statistics & numerical data]; 9. Hospitalization [statistics & numerical data]; 10. Randomized Controlled Trials as Topic; 11. Self‐Management [*methods];
MESH terms:
Antibiotics for treating urogenital Chlamydia trachomatis infection in men and non‐pregnant women
1. Anti-Bacterial Agents [adverse effects, *therapeutic use]; 2. Asymptomatic Infections [therapy]; 3. Azithromycin [adverse effects, *therapeutic use]; 4. Chlamydia Infections [*drug therapy]; 5. *Chlamydia trachomatis; 6. Doxycycline [adverse effects, *therapeutic use]; 7. Ofloxacin [therapeutic use]; 8. Randomized Controlled Trials as Topic; 9. Sex Factors; 10. Treatment Outcome; 11. Urinary Tract Infections [drug therapy];
MESH terms:
Surgical versus conservative interventions for treating fractures of the middle third of the clavicle
1. *Bandages; 2. Clavicle [*injuries]; 3. Conservative Treatment [*methods]; 4. Fracture Fixation [adverse effects, instrumentation, *methods]; 5. Fractures, Bone [surgery, *therapy]; 6. Pain Measurement; 7. Quality of Life; 8. Randomized Controlled Trials as Topic; 9. *Splints; 10. Treatment Outcome;
MESH terms:
Oral H1 antihistamines as ‘add‐on’ therapy to topical treatment for eczema
1. Administration, Oral; 2. Administration, Topical; 3. Cetirizine [administration & dosage, adverse effects]; 4. Chemotherapy, Adjuvant; 5. Eczema [*drug therapy]; 6. Histamine H1 Antagonists [*administration & dosage, adverse effects]; 7. Loratadine [administration & dosage, adverse effects]; 8. Outcome Assessment, Health Care; 9. Pruritus [drug therapy, etiology]; 10. Randomized Controlled Trials as Topic; 11. Terfenadine [administration & dosage, adverse effects, analogs & derivatives];
MESH terms:
Inpatient versus outpatient care, partial hospitalisation and waiting list for people with eating disorders
1. *Ambulatory Care [statistics & numerical data]; 2. Anorexia Nervosa [*therapy]; 3. Body Mass Index; 4. Body Weight; 5. Bulimia Nervosa [*therapy]; 6. Confidence Intervals; 7. Feeding and Eating Disorders [therapy]; 8. *Hospitalization [statistics & numerical data]; 9. Length of Stay [statistics & numerical data]; 10. Randomized Controlled Trials as Topic; 11. Remission Induction; 12. Waiting Lists;
MESH terms:
Adverse events in people taking macrolide antibiotics versus placebo for any indication
1. Abdominal Pain [chemically induced]; 2. Anti‐Bacterial Agents [*adverse effects]; 3. Bile Duct Diseases [chemically induced]; 4. Diarrhea [chemically induced]; 5. Hearing Loss [chemically induced]; 6. Heart Diseases [chemically induced]; 7. Macrolides [*adverse effects, therapeutic use]; 8. Nausea [chemically induced]; 9. Numbers Needed To Treat; 10. Placebos; 11. Randomized Controlled Trials as Topic; 12. Taste Disorders [chemically induced]; 13. Vomiting [chemically induced];
MESH terms:
Adrenaline and vasopressin for cardiac arrest
1. Blood Circulation [*drug effects, physiology]; 2. Epinephrine [*administration & dosage]; 3. Heart [drug effects]; 4. Heart Arrest [*drug therapy, mortality, physiopathology]; 5. Out‐of‐Hospital Cardiac Arrest [drug therapy, mortality]; 6. Patient Admission [*statistics & numerical data]; 7. Patient Discharge [*statistics & numerical data]; 8. Placebos [administration & dosage]; 9. Randomized Controlled Trials as Topic; 10. Survival Analysis; 11. Vasoconstrictor Agents [*administration & dosage]; 12. Vasopressins [*administration & dosage];
MESH terms:
Postoperative epidural analgesia versus systemic analgesia for thoraco‐lumbar spine surgery in children
1. *Analgesia, Epidural [adverse effects]; 2. Analgesia [adverse effects, *methods]; 3. Early Ambulation [statistics & numerical data]; 4. Lumbar Vertebrae [*surgery]; 5. Operative Time; 6. Pain Measurement; 7. Pain, Postoperative [*drug therapy]; 8. Patient Satisfaction; 9. Randomized Controlled Trials as Topic; 10. Thoracic Vertebrae [*surgery]; 11. Vomiting [chemically induced];
MESH terms:
Antiamoebic drugs for treating amoebic colitis
1. *Entamoeba histolytica; 2. Amebicides [adverse effects, *therapeutic use]; 3. Drug Therapy, Combination; 4. Dysentery, Amebic [*drug therapy, parasitology]; 5. Metronidazole [adverse effects, therapeutic use]; 6. Randomized Controlled Trials as Topic; 7. Tinidazole [adverse effects, therapeutic use];
MESH terms:
Potentiators (specific therapies for class III and IV mutations) for cystic fibrosis
1. Age Factors; 2. Aminophenols [adverse effects, *therapeutic use]; 3. Chloride Channel Agonists [adverse effects, *therapeutic use]; 4. Clinical Trials, Phase II as Topic; 5. Clinical Trials, Phase III as Topic; 6. Cystic Fibrosis [*drug therapy, *genetics]; 7. Cystic Fibrosis Transmembrane Conductance Regulator [drug effects, *genetics]; 8. Forced Expiratory Volume [drug effects]; 9. Molecular Targeted Therapy [methods]; 10. Mucociliary Clearance; 11. Mutation [*genetics]; 12. Quality of Life; 13. Quinolones [adverse effects, *therapeutic use]; 14. Randomized Controlled Trials as Topic;
MESH terms:
Transfusion of red blood cells stored for shorter versus longer duration for all conditions
1. Anemia [etiology, mortality, *therapy]; 2. Anemia, Sickle Cell [complications]; 3. *Blood Preservation [adverse effects, mortality]; 4. Blood Safety; 5. *Erythrocyte Transfusion [adverse effects, mortality]; 6. *Erythrocytes; 7. Guidelines as Topic; 8. Hospital Mortality; 9. Infant, Very Low Birth Weight; 10. Malaria [complications]; 11. Randomized Controlled Trials as Topic; 12. Sample Size; 13. Time Factors;
MESH terms:
Interventions for treating wrist fractures in children
1. Bandages [*statistics & numerical data]; 2. Fracture Fixation [adverse effects, *methods]; 3. Fracture Healing; 4. Immobilization [methods, statistics & numerical data]; 5. Pain Measurement; 6. Radius Fractures [*therapy]; 7. Randomized Controlled Trials as Topic; 8. Splints [*statistics & numerical data]; 9. Time Factors; 10. Treatment Failure; 11. Wrist Injuries;
MESH terms:
First aid interventions by laypeople for acute oral poisoning
1. Acetaminophen [poisoning]; 2. Analgesics, Non-Narcotic [poisoning]; 3. Antidepressive Agents [poisoning]; 4. Antidotes [therapeutic use]; 5. Benzodiazepines [poisoning]; 6. Carbamazepine [poisoning]; 7. Cathartics [therapeutic use]; 8. Charcoal [therapeutic use]; 9. First Aid [*methods]; 10. Fruit [poisoning]; 11. Ipecac [therapeutic use]; 12. Poisoning [etiology, *therapy]; 13. Publication Bias; 14. Randomized Controlled Trials as Topic; 15. Thevetia [poisoning];
MESH terms:
Sedation of children undergoing dental treatment
1. Analgesics, Non‐Narcotic [administration & dosage]; 2. Anti‐Anxiety Agents [administration & dosage, *therapeutic use]; 3. Chloral Hydrate [administration & dosage]; 4. Dental Anxiety [*drug therapy]; 5. Dental Care for Children [methods, *psychology]; 6. Hydroxyzine [administration & dosage]; 7. Hypnotics and Sedatives [administration & dosage, *therapeutic use]; 8. Meperidine [administration & dosage]; 9. Midazolam [administration & dosage]; 10. Nitrous Oxide [administration & dosage]; 11. Preanesthetic Medication [methods]; 12. Randomized Controlled Trials as Topic;
MESH terms:
Short‐acting insulin analogues versus regular human insulin for adult, non‐pregnant persons with type 2 diabetes mellitus
1. Diabetes Mellitus, Type 2 [blood, *drug therapy, mortality]; 2. Hypoglycemic Agents [*therapeutic use]; 3. Insulin [*analogs & derivatives, *therapeutic use]; 4. Insulin Aspart [*therapeutic use]; 5. Insulin Lispro [*therapeutic use]; 6. Quality of Life; 7. Randomized Controlled Trials as Topic;
MESH terms:
Maternal probiotic supplementation for prevention of morbidity and mortality in preterm infants
1. Administration, Oral; 2. Enterocolitis, Necrotizing [*prevention & control]; 3. Gastrointestinal Microbiome; 4. Infant Mortality; 5. *Infant, Premature; 6. Infant, Premature, Diseases [*prevention & control]; 7. Inflammation; 8. Morbidity; 9. *Mothers; 10. Prenatal Care; 11. Probiotics [*administration & dosage]; 12. Randomized Controlled Trials as Topic;
MESH terms:
Liberal versus conservative fluid therapy in adults and children with sepsis or septic shock
1. Cause of Death; 2. Fluid Therapy [adverse effects, *methods]; 3. Hospital Mortality; 4. Randomized Controlled Trials as Topic; 5. Sepsis [mortality, *therapy]; 6. Shock, Septic [therapy];
MESH terms:
Dressings and topical agents for preventing pressure ulcers
1. *Bandages; 2. Administration, Cutaneous; 3. Allantoin [administration & dosage]; 4. Dimethyl Sulfoxide [administration & dosage]; 5. Drug Administration Schedule; 6. Drug Combinations; 7. Fatty Acids [administration & dosage]; 8. Hexachlorophene [administration & dosage]; 9. Incidence; 10. Olive Oil [administration & dosage]; 11. Pressure Ulcer [epidemiology, *prevention & control]; 12. Randomized Controlled Trials as Topic; 13. Silicones [administration & dosage]; 14. Skin Care [*methods]; 15. Skin Cream [*administration & dosage, chemistry]; 16. Squalene [administration & dosage];
MESH terms:
Oral and intrauterine progestogens for atypical endometrial hyperplasia
1. Administration, Oral; 2. Endometrial Hyperplasia [*drug therapy]; 3. *Intrauterine Devices, Medicated; 4. Levonorgestrel [*administration & dosage]; 5. Medroxyprogesterone [*administration & dosage]; 6. Randomized Controlled Trials as Topic;
MESH terms:
Inhaled steroids with and without regular salmeterol for asthma: serious adverse events
1. Adrenal Cortex Hormones [administration & dosage, *adverse effects]; 2. Adrenergic beta‐2 Receptor Agonists [administration & dosage, *adverse effects]; 3. Age Factors; 4. Albuterol [administration & dosage, adverse effects, *analogs & derivatives]; 5. Anti‐Asthmatic Agents [administration & dosage, *adverse effects]; 6. Asthma [drug therapy, *mortality]; 7. Cause of Death; 8. Randomized Controlled Trials as Topic; 9. Salmeterol Xinafoate;
MESH terms:
Laparoscopic versus open surgery for suspected appendicitis
1. *Laparoscopy [adverse effects]; 2. Abdominal Abscess [epidemiology]; 3. Acute Disease; 4. Appendectomy [adverse effects, *methods]; 5. Appendicitis [diagnosis, *surgery]; 6. Pain, Postoperative [epidemiology]; 7. Randomized Controlled Trials as Topic; 8. Recovery of Function; 9. Surgical Wound Infection [epidemiology]; 10. Time Factors;
MESH terms:
Oral isotretinoin for acne
1. Administration, Oral; 2. Anti‐Bacterial Agents [administration & dosage]; 3. Dermatologic Agents [*administration & dosage, adverse effects]; 4. Isotretinoin [*administration & dosage, adverse effects]; 5. Randomized Controlled Trials as Topic;
MESH terms:
Omega‐3 fatty acid addition during pregnancy
1. *Infant, Small for Gestational Age; 2. Dietary Supplements; 3. Fatty Acids, Omega‐3 [*administration & dosage]; 4. Fetal Death [prevention & control]; 5. Fetal Growth Retardation [*prevention & control]; 6. Fish Oils [administration & dosage]; 7. Gestational Age; 8. Infant, Low Birth Weight; 9. Infant, Postmature; 10. Pre‐Eclampsia [*prevention & control]; 11. Pregnancy, High‐Risk; 12. Premature Birth [*prevention & control]; 13. Randomized Controlled Trials as Topic; 14. Seafood;
MESH terms:
Phonics training for English‐speaking poor readers
1. Australia; 2. Canada; 3. *Comprehension; 4. Dyslexia [*rehabilitation]; 5. Language; 6. Phonation [*physiology]; 7. *Phonetics; 8. Randomized Controlled Trials as Topic; 9. *Reading; 10. Socioeconomic Factors; 11. United Kingdom; 12. United States;
MESH terms:
Protocol‐directed sedation versus non‐protocol‐directed sedation in mechanically ventilated intensive care adults and children
1. *Algorithms; 2. *Clinical Protocols; 3. *Conscious Sedation; 4. *Critical Care; 5. *Critical Illness; 6. *Respiration, Artificial; 7. Analgesics [*administration & dosage]; 8. Hospital Mortality; 9. Hypnotics and Sedatives [*administration & dosage]; 10. Length of Stay; 11. Practice Patterns, Nurses'; 12. Publication Bias; 13. Randomized Controlled Trials as Topic; 14. Selection Bias; 15. Time Factors;
MESH terms:
Communication interventions for autism spectrum disorder in minimally verbal children
1. Autism Spectrum Disorder [*complications]; 2. Language Development Disorders [complications, *therapy]; 3. Language Tests; 4. Language Therapy [*methods]; 5. *Nonverbal Communication; 6. Parents [education]; 7. Play Therapy [*methods]; 8. Randomized Controlled Trials as Topic; 9. School Teachers; 10. Teacher Training; 11. Treatment Outcome;
MESH terms:
Caseworker‐assigned discharge plans to prevent hospital readmission for acute exacerbations in children with chronic respiratory illness
1. *Disease Progression; 2. *Patient Discharge; 3. *Patient Readmission; 4. Asthma [*therapy]; 5. Case Management [*organization & administration]; 6. Chronic Disease; 7. Emergency Service, Hospital [statistics & numerical data]; 8. General Practice [statistics & numerical data]; 9. Health Educators; 10. Hospitalization [statistics & numerical data]; 11. Randomized Controlled Trials as Topic; 12. Respiratory Tract Diseases [*therapy]; 13. Transitional Care [*organization & administration];
MESH terms:
One‐to‐one oral hygiene advice provided in a dental setting for oral health
1. *Oral Health; 2. Dental Care; 3. Dental Caries [*prevention & control]; 4. Dental Offices; 5. Dental Plaque [*prevention & control]; 6. Gingivitis [*prevention & control]; 7. Oral Hygiene [*education, methods]; 8. Randomized Controlled Trials as Topic; 9. Self Care;
MESH terms:
Biocompatible dialysis fluids for peritoneal dialysis
1. *Peritoneum [drug effects, injuries]; 2. Bicarbonates [chemistry, therapeutic use]; 3. Dialysis Solutions [adverse effects, *chemistry]; 4. Glucose [metabolism, therapeutic use]; 5. Hydrogen‐Ion Concentration; 6. Icodextrin [therapeutic use]; 7. Kidney [physiology]; 8. Peritoneal Dialysis [*methods]; 9. Pharmaceutical Solutions [chemistry, therapeutic use]; 10. Randomized Controlled Trials as Topic; 11. Urine;
MESH terms:
Carbamazepine versus phenobarbitone monotherapy for epilepsy: an individual participant data review
1. Anticonvulsants [adverse effects, *therapeutic use]; 2. Carbamazepine [adverse effects, *therapeutic use]; 3. Epilepsies, Partial [*drug therapy]; 4. Epilepsy, Generalized [*drug therapy]; 5. Epilepsy, Tonic‐Clonic [drug therapy]; 6. Phenobarbital [adverse effects, *therapeutic use]; 7. Randomized Controlled Trials as Topic; 8. Recurrence; 9. Remission Induction; 10. Seizures [prevention & control]; 11. Time Factors; 12. Treatment Failure;
MESH terms:
Oxcarbazepine versus phenytoin monotherapy for epilepsy: an individual participant data review
1. Anticonvulsants [adverse effects, *therapeutic use]; 2. Epilepsies, Partial [*drug therapy]; 3. Epilepsy, Tonic‐Clonic [*drug therapy]; 4. Induction Chemotherapy; 5. Oxcarbazepine [adverse effects, *therapeutic use]; 6. Phenytoin [adverse effects, *therapeutic use]; 7. Proportional Hazards Models; 8. Randomized Controlled Trials as Topic; 9. Treatment Failure;
MESH terms:
Leukotriene receptor antagonists for eczema
1. Acetates [administration & dosage, adverse effects, *therapeutic use]; 2. Administration, Oral; 3. Cyclopropanes; 4. Eczema [*drug therapy]; 5. Leukotriene Antagonists [administration & dosage, adverse effects, *therapeutic use]; 6. Quinolines [administration & dosage, adverse effects, *therapeutic use]; 7. Randomized Controlled Trials as Topic; 8. Sulfides;
MESH terms:
Interventions for preventing and treating cardiac complications in Duchenne and Becker muscular dystrophy and X‐linked dilated cardiomyopathy
1. Angiotensin Receptor Antagonists [adverse effects, *therapeutic use]; 2. Angiotensin‐Converting Enzyme Inhibitors [adverse effects, *therapeutic use]; 3. Antihypertensive Agents [therapeutic use]; 4. Cardiomyopathies [*drug therapy, etiology, prevention & control]; 5. Cardiomyopathy, Dilated [*complications]; 6. Cardiovascular Agents [therapeutic use]; 7. Disease Progression; 8. Eplerenone [adverse effects, therapeutic use]; 9. Human Growth Hormone [therapeutic use]; 10. Lisinopril [therapeutic use]; 11. Losartan [therapeutic use]; 12. Muscular Dystrophy, Duchenne [*complications]; 13. Non‐Randomized Controlled Trials as Topic; 14. Perindopril [therapeutic use]; 15. Placebos [adverse effects, therapeutic use]; 16. Randomized Controlled Trials as Topic; 17. Stroke Volume [drug effects]; 18. Ubiquinone [adverse effects, analogs & derivatives, therapeutic use];
MESH terms:
Parent‐mediated interventions for promoting communication and language development in young children with Down syndrome
1. *Child Language; 2. *Communication; 3. *Down Syndrome; 4. Language Therapy [*methods]; 5. Mothers; 6. *Parents; 7. Randomized Controlled Trials as Topic; 8. Social Skills; 9. Time Factors;
MESH terms:
Dietary modifications for infantile colic
1. *Infant Formula; 2. Allergens; 3. Colic [*diet therapy]; 4. Crying; 5. Diet Therapy [methods]; 6. Lactase [administration & dosage]; 7. Randomized Controlled Trials as Topic; 8. Soybean Proteins [administration & dosage]; 9. Time Factors;
MESH terms:
Eszopiclone for insomnia
1. Eszopiclone [*therapeutic use]; 2. Hypnotics and Sedatives [*therapeutic use]; 3. Randomized Controlled Trials as Topic; 4. Sleep Initiation and Maintenance Disorders [*drug therapy]; 5. Time Factors; 6. Treatment Outcome;
MESH terms:
Psychological interventions for needle‐related procedural pain and distress in children and adolescents
1. Anxiety [*prevention & control, psychology]; 2. Central Venous Catheters [adverse effects]; 3. Cognitive Behavioral Therapy [*methods]; 4. Hypnosis; 5. Immunization; 6. *Needles; 7. Pain, Procedural [*prevention & control, *psychology]; 8. Phlebotomy [psychology]; 9. Punctures [*psychology]; 10. Randomized Controlled Trials as Topic; 11. Self Report;
MESH terms:
Calcium supplementation during pregnancy for preventing hypertensive disorders and related problems
1. Calcium [*administration & dosage]; 2. *Dietary Supplements; 3. Hypertension [mortality, *prevention & control]; 4. Linoleic Acid [administration & dosage]; 5. Pre-Eclampsia [mortality, *prevention & control]; 6. Pregnancy Complications, Cardiovascular [mortality, *prevention & control]; 7. Premature Birth [*prevention & control]; 8. Randomized Controlled Trials as Topic; 9. Vitamin D [administration & dosage]; 10. Vitamins [administration & dosage];
MESH terms:
Psychological therapies for the management of chronic and recurrent pain in children and adolescents
1. Abdominal Pain [therapy]; 2. Anxiety [drug therapy]; 3. Chronic Pain [etiology, psychology, *therapy]; 4. Cognitive Behavioral Therapy; 5. Depression [drug therapy]; 6. Fibromyalgia [therapy]; 7. Headache [therapy]; 8. Hemoglobin SC Disease [complications]; 9. Pain Management [*methods, psychology]; 10. Psychotherapy [*methods]; 11. Randomized Controlled Trials as Topic; 12. Recurrence; 13. Temporomandibular Joint Disorders [therapy];
MESH terms:
Antibiotics for treating scrub typhus
1. Anti‐Bacterial Agents [*therapeutic use]; 2. Azithromycin [therapeutic use]; 3. Chloramphenicol [therapeutic use]; 4. Doxycycline [therapeutic use]; 5. Macrolides [therapeutic use]; 6. Randomized Controlled Trials as Topic; 7. Rifampin [therapeutic use]; 8. Scrub Typhus [*drug therapy]; 9. Tetracycline [therapeutic use];
MESH terms:
Insulin and glucose‐lowering agents for treating people with diabetes and chronic kidney disease
1. Cause of Death; 2. Diabetes Mellitus [blood, *drug therapy, mortality]; 3. Diabetic Nephropathies [blood, *drug therapy, mortality]; 4. Dipeptidyl-Peptidase IV Inhibitors [therapeutic use]; 5. Glipizide [adverse effects, therapeutic use]; 6. Glucagon-Like Peptide 1 [agonists]; 7. Glycated Hemoglobin [drug effects]; 8. Hypoglycemic Agents [adverse effects, *therapeutic use]; 9. Insulin [adverse effects, *therapeutic use]; 10. Randomized Controlled Trials as Topic; 11. Renal Insufficiency, Chronic [blood, *drug therapy, mortality]; 12. Sitagliptin Phosphate [adverse effects, therapeutic use]; 13. Sodium-Glucose Transporter 2; 14. Sodium-Glucose Transporter 2 Inhibitors; 15. Thiazolidinediones [therapeutic use];
MESH terms:
Topical and systemic antifungal therapy for chronic rhinosinusitis
1. Administration, Topical; 2. Amphotericin B [*administration & dosage, adverse effects]; 3. Antifungal Agents [*administration & dosage, adverse effects]; 4. Chronic Disease; 5. Fluconazole [*administration & dosage, adverse effects]; 6. Quality of Life; 7. Randomized Controlled Trials as Topic; 8. Rhinitis [*drug therapy]; 9. Sinusitis [*drug therapy];
MESH terms:
Oropharyngeal colostrum in preventing mortality and morbidity in preterm infants
1. Administration, Oral; 2. Colostrum [*immunology]; 3. Enterocolitis, Necrotizing [immunology, *prevention & control]; 4. Hospital Mortality; 5. Immunity, Mucosal [immunology]; 6. Infant, Premature [*immunology]; 7. Length of Stay; 8. Mouth Mucosa [*immunology]; 9. Oropharynx; 10. Randomized Controlled Trials as Topic; 11. Sepsis [*prevention & control];
MESH terms:
Head‐to‐head trials of antibiotics for bronchiectasis
1. Aminoglycosides [*therapeutic use]; 2. Amoxicillin [therapeutic use]; 3. Anti‐Bacterial Agents [*therapeutic use]; 4. Bronchiectasis [*drug therapy]; 5. Fluoroquinolones [*therapeutic use]; 6. Forced Expiratory Volume; 7. Polymyxins [*therapeutic use]; 8. Pseudomonas Infections [drug therapy]; 9. Randomized Controlled Trials as Topic; 10. beta‐Lactams [*therapeutic use];
MESH terms:
Autologous cells derived from different sources and administered using different regimens for 'no‐option' critical lower limb ischaemia patients
1. Amputation, Surgical [statistics & numerical data]; 2. Bone Marrow Cells [cytology]; 3. Bone Marrow Transplantation [*methods]; 4. Cause of Death; 5. Injections, Intra-Arterial; 6. Injections, Intramuscular; 7. Ischemia [*therapy]; 8. Leg [*blood supply]; 9. Leg Ulcer [therapy]; 10. Mesenchymal Stem Cell Transplantation [*methods]; 11. Peripheral Blood Stem Cell Transplantation [*methods]; 12. Peripheral Blood Stem Cells [cytology]; 13. Randomized Controlled Trials as Topic;
MESH terms:
Impact of medication reconciliation for improving transitions of care
1. *Medication Reconciliation [statistics & numerical data]; 2. *Transitional Care; 3. Drug‐Related Side Effects and Adverse Reactions [*prevention & control]; 4. Medication Errors [*prevention & control]; 5. Patient Readmission [statistics & numerical data]; 6. Pharmacists; 7. Quality Improvement; 8. Randomized Controlled Trials as Topic;
MESH terms:
Drugs for treating Buruli ulcer (Mycobacterium ulcerans disease)
1. Anti-Bacterial Agents [*therapeutic use]; 2. Buruli Ulcer [complications, *drug therapy, surgery]; 3. Clarithromycin [therapeutic use]; 4. Clofazimine [therapeutic use]; 5. Drug Therapy, Combination; 6. Mycobacterium ulcerans; 7. Observational Studies as Topic; 8. Randomized Controlled Trials as Topic; 9. Rifampin [therapeutic use]; 10. Streptomycin [therapeutic use]; 11. Trimethoprim, Sulfamethoxazole Drug Combination [therapeutic use];
MESH terms:
Client feedback in psychological therapy for children and adolescents with mental health problems
1. *Feedback, Psychological; 2. *Patient Reported Outcome Measures; 3. Clinical Decision‐Making; 4. Mental Disorders [*therapy]; 5. Patient Dropouts [statistics & numerical data]; 6. Psychotherapy [*methods]; 7. Randomized Controlled Trials as Topic; 8. Treatment Outcome;
MESH terms:
Xenon as an adjuvant to therapeutic hypothermia in near‐term and term newborns with hypoxic‐ischaemic encephalopathy
1. Child Development; 2. Combined Modality Therapy; 3. Hypothermia, Induced [*methods]; 4. Hypoxia‐Ischemia, Brain [mortality, *therapy]; 5. Xenon [*therapeutic use];
MESH terms:
E‐Health interventions for anxiety and depression in children and adolescents with long‐term physical conditions
1. Anxiety [*therapy]; 2. Breathing Exercises [*methods]; 3. Chronic Disease [*psychology]; 4. Cognitive Behavioral Therapy [*methods]; 5. Depression [*therapy]; 6. Randomized Controlled Trials as Topic; 7. Telemedicine [*methods]; 8. Treatment Outcome;
MESH terms:
Enteral nutrition for maintenance of remission in Crohn's disease
1. *Enteral Nutrition; 2. *Secondary Prevention; 3. Anti‐Inflammatory Agents, Non‐Steroidal [adverse effects, therapeutic use]; 4. Antimetabolites [adverse effects, therapeutic use]; 5. Crohn Disease [prevention & control, *therapy]; 6. Diet; 7. Food, Formulated; 8. Maintenance Chemotherapy [methods]; 9. Mercaptopurine [adverse effects, therapeutic use]; 10. Mesalamine [adverse effects, therapeutic use]; 11. Randomized Controlled Trials as Topic;
MESH terms:
Sodium valproate versus phenytoin monotherapy for epilepsy: an individual participant data review
1. Anticonvulsants [*therapeutic use]; 2. Epilepsies, Partial [*drug therapy]; 3. Epilepsy, Generalized [*drug therapy]; 4. Phenytoin [*therapeutic use]; 5. Randomized Controlled Trials as Topic; 6. Seizures [*drug therapy]; 7. Treatment Outcome; 8. Valproic Acid [*therapeutic use];
MESH terms:
Needle size for vaccination procedures in children and adolescents
1. *Needles [adverse effects]; 2. Crying; 3. Diphtheria [immunology, prevention & control]; 4. Equipment Design; 5. Haemophilus Infections [immunology, prevention & control]; 6. Haemophilus influenzae type b [immunology]; 7. Immunization [*instrumentation, methods]; 8. Injections, Intramuscular [instrumentation, methods]; 9. Pain, Procedural [*prevention & control]; 10. Randomized Controlled Trials as Topic; 11. Tetanus [immunology, prevention & control]; 12. Vaccines [administration & dosage, immunology];
MESH terms:
Vitamin A and beta (β)‐carotene supplementation for cystic fibrosis
1. beta Carotene [*administration & dosage]; 2. Cystic Fibrosis [*complications]; 3. Provitamins [*administration & dosage]; 4. Randomized Controlled Trials as Topic; 5. Vitamin A [*administration & dosage, adverse effects]; 6. Vitamin A Deficiency [*prevention & control]; 7. Vitamins [*administration & dosage, adverse effects];
MESH terms:
Colloids versus crystalloids for fluid resuscitation in critically ill people
1. *Rehydration Solutions; 2. Colloids [adverse effects, *therapeutic use]; 3. Critical Illness [mortality, *therapy]; 4. Crystalloid Solutions [adverse effects, *therapeutic use]; 5. Fluid Therapy [*methods, mortality]; 6. Isotonic Solutions; 7. Plasma Substitutes [*therapeutic use]; 8. Randomized Controlled Trials as Topic; 9. Renal Replacement Therapy [statistics & numerical data];
MESH terms:
Antibiotics for prolonged wet cough in children
1. Amoxicillin‐Potassium Clavulanate Combination [adverse effects, *therapeutic use]; 2. Anti‐Bacterial Agents [adverse effects, *therapeutic use]; 3. Chronic Disease; 4. Cough [classification, *drug therapy]; 5. Disease Progression; 6. Erythromycin [adverse effects, *therapeutic use]; 7. Intention to Treat Analysis; 8. Randomized Controlled Trials as Topic; 9. Sputum [metabolism];
MESH terms:
Treatment for chronic methicillin‐sensitive Staphylococcus aureus pulmonary infection in people with cystic fibrosis
1. *Staphylococcus aureus [drug effects]; 2. Anti‐Bacterial Agents [*therapeutic use]; 3. Cystic Fibrosis [*microbiology]; 4. Methicillin [*therapeutic use]; 5. Respiratory Tract Infections [*drug therapy, microbiology]; 6. Staphylococcal Infections [*drug therapy];
MESH terms:
Ear drops for the removal of ear wax
1. Antipyrine [therapeutic use]; 2. Benzocaine [therapeutic use]; 3. Carbamide Peroxide; 4. Carbonates [therapeutic use]; 5. *Cerumen; 6. Chlorobutanol [therapeutic use]; 7. Choline [analogs & derivatives, therapeutic use]; 8. Dioctyl Sulfosuccinic Acid [therapeutic use]; 9. Drug Combinations; 10. *Ear Canal; 11. Ethanolamines [therapeutic use]; 12. *Hygiene; 13. Peroxides [therapeutic use]; 14. Pharmaceutical Solutions [therapeutic use]; 15. Plant Oils [therapeutic use]; 16. Potassium [therapeutic use]; 17. Randomized Controlled Trials as Topic; 18. Salicylates [therapeutic use]; 19. Sodium Chloride [therapeutic use]; 20. Surface-Active Agents [*therapeutic use]; 21. Urea [analogs & derivatives, therapeutic use]; 22. Water;
MESH terms:
Parent‐mediated communication interventions for improving the communication skills of preschool children with non‐progressive motor disorders
1. *Communication; 2. *Mother‐Child Relations; 3. Canada; 4. Facial Expression; 5. Mothers [*education]; 6. Motor Disorders [*complications]; 7. Randomized Controlled Trials as Topic; 8. Republic of Korea; 9. Speech Disorders [etiology, *rehabilitation];
MESH terms:
Parent training interventions for parents with intellectual disability
1. *Child of Impaired Parents; 2. *Child Rearing; 3. Fathers [*education]; 4. Mother-Child Relations; 5. Mothers [*education]; 6. *Parenting; 7. *Persons with Mental Disabilities; 8. Randomized Controlled Trials as Topic; 9. Safety;
MESH terms:
Psychological therapies for the treatment of mental disorders in low‐ and middle‐income countries affected by humanitarian crises
1. *Developing Countries; 2. Age Factors; 3. Anxiety Disorders [psychology, *therapy]; 4. Armed Conflicts [psychology]; 5. Behavior Therapy; 6. Depressive Disorder, Major [psychology, *therapy]; 7. Disasters; 8. Eye Movement Desensitization Reprocessing [methods]; 9. Narrative Therapy; 10. Patient Dropouts [statistics & numerical data]; 11. Psychotherapy [*methods]; 12. Randomized Controlled Trials as Topic; 13. Somatoform Disorders [therapy]; 14. Stress Disorders, Post‐Traumatic [psychology, *therapy]; 15. Stress, Psychological [complications]; 16. Violence [psychology]; 17. Waiting Lists;
MESH terms:
Effects of total fat intake on bodyweight in children
1. Body Mass Index; 2. *Body Weight; 3. *Diet, Fat-Restricted; 4. Dietary Fats [*administration & dosage]; 5. Energy Intake; 6. *Pediatric Obesity; 7. Prospective Studies; 8. Randomized Controlled Trials as Topic;
MESH terms:
Negative pressure wound therapy for open traumatic wounds
1. Fractures, Open [*therapy]; 2. Negative‐Pressure Wound Therapy [*methods]; 3. Quality of Life; 4. Quality‐Adjusted Life Years; 5. Randomized Controlled Trials as Topic; 6. Soft Tissue Injuries [*therapy]; 7. Wound Healing; 8. Wound Infection [prevention & control];
MESH terms:
Antifibrinolytic therapy for preventing oral bleeding in people on anticoagulants undergoing minor oral surgery or dental extractions
1. Anticoagulants [administration & dosage, *adverse effects]; 2. Antifibrinolytic Agents [*therapeutic use]; 3. Minor Surgical Procedures [*adverse effects]; 4. Oral Hemorrhage [chemically induced, *prevention & control]; 5. Oral Surgical Procedures [*adverse effects]; 6. Tooth Extraction [adverse effects]; 7. Tranexamic Acid [*therapeutic use];
MESH terms:
Lamotrigine versus carbamazepine monotherapy for epilepsy: an individual participant data review
1. Anticonvulsants [adverse effects, *therapeutic use]; 2. Carbamazepine [adverse effects, *therapeutic use]; 3. Epilepsies, Partial [*drug therapy]; 4. Epilepsy, Generalized [drug therapy]; 5. Epilepsy, Tonic‐Clonic [*drug therapy]; 6. Lamotrigine; 7. Randomized Controlled Trials as Topic; 8. Recurrence; 9. Time Factors; 10. Treatment Failure; 11. Triazines [*therapeutic use]; 12. Withholding Treatment;
MESH terms:
Pharmacological treatment for attention deficit hyperactivity disorder (ADHD) in children with comorbid tic disorders
1. Atomoxetine Hydrochloride [therapeutic use]; 2. Attention Deficit Disorder with Hyperactivity [*drug therapy]; 3. Central Nervous System Stimulants [adverse effects, *therapeutic use]; 4. Clonidine [therapeutic use]; 5. Desipramine [therapeutic use]; 6. Dextroamphetamine [therapeutic use]; 7. Guanfacine [therapeutic use]; 8. Methylphenidate [therapeutic use]; 9. Randomized Controlled Trials as Topic; 10. Selegiline; 11. Tic Disorders [*complications, drug therapy];
MESH terms:
Antibiotics for exacerbations of asthma
1. Acute Disease; 2. Age Factors; 3. Amoxicillin [therapeutic use]; 4. Ampicillin [therapeutic use]; 5. Anti‐Bacterial Agents [adverse effects, *therapeutic use]; 6. Asthma [*drug therapy]; 7. Disease Progression; 8. Length of Stay; 9. Macrolides [therapeutic use]; 10. Randomized Controlled Trials as Topic;
MESH terms:
Early planned removal versus expectant management of peripherally inserted central catheters to prevent infection in newborn infants
1. *Device Removal; 2. *Watchful Waiting; 3. Catheter‐Related Infections [*prevention & control]; 4. Catheterization, Peripheral [*adverse effects]; 5. Time Factors;
MESH terms:
Local anaesthetics and regional anaesthesia versus conventional analgesia for preventing persistent postoperative pain in adults and children
1. Amputation, Surgical [adverse effects]; 2. Analgesia [*methods]; 3. *Anesthesia, Conduction; 4. *Anesthetics, Local; 5. Breast Neoplasms [*surgery]; 6. Cesarean Section [*adverse effects]; 7. Chronic Pain [*prevention & control]; 8. Laparotomy [adverse effects]; 9. Nerve Block [methods]; 10. Pain, Postoperative [epidemiology, *prevention & control]; 11. Randomized Controlled Trials as Topic; 12. Thoracotomy [*adverse effects]; 13. Time Factors; 14. Tissue and Organ Harvesting [adverse effects];
MESH terms:
Nurse‐led versus doctor‐led care for bronchiectasis
1. Bronchiectasis [*nursing]; 2. Randomized Controlled Trials as Topic;
MESH terms:
Immunosuppressive drug therapy for preventing rejection following lung transplantation in cystic fibrosis
1. Cystic Fibrosis [*surgery]; 2. Graft Rejection [*prevention & control]; 3. Immunosuppressive Agents [*therapeutic use]; 4. *Lung Transplantation;
MESH terms:
Dual antibiotics for bronchiectasis
1. Anti‐Bacterial Agents [*therapeutic use]; 2. Bronchiectasis [*drug therapy, microbiology]; 3. Ciprofloxacin [*therapeutic use]; 4. Gentamicins [*therapeutic use]; 5. Pseudomonas Infections [*drug therapy]; 6. Pseudomonas aeruginosa; 7. Randomized Controlled Trials as Topic; 8. Tobramycin [*therapeutic use];
MESH terms:
Ribavirin for treating Crimean Congo haemorrhagic fever
1. Antiviral Agents [*therapeutic use]; 2. Hemorrhagic Fever, Crimean [*drug therapy, mortality]; 3. Length of Stay; 4. Non-Randomized Controlled Trials as Topic; 5. Randomized Controlled Trials as Topic; 6. Ribavirin [*therapeutic use];
MESH terms:
Continuous versus intermittent antibiotics for bronchiectasis
1. Anti‐Bacterial Agents [administration & dosage, *therapeutic use]; 2. Bronchiectasis [*drug therapy];
MESH terms:
Intramuscular versus oral corticosteroids to reduce relapses following discharge from the emergency department for acute asthma
1. *Secondary Prevention; 2. Acute Disease; 3. Administration, Oral; 4. Adrenal Cortex Hormones [*administration & dosage]; 5. Anti‐Asthmatic Agents [*administration & dosage]; 6. Asthma [drug therapy, *prevention & control]; 7. Betamethasone [administration & dosage]; 8. Dexamethasone [administration & dosage]; 9. Emergency Service, Hospital; 10. Injections, Intramuscular; 11. Methylprednisolone [administration & dosage]; 12. Patient Discharge; 13. Prednisolone [administration & dosage]; 14. Prednisone [administration & dosage]; 15. Randomized Controlled Trials as Topic; 16. Recurrence; 17. Triamcinolone [administration & dosage];
MESH terms:
Interventions for childhood apraxia of speech
1. *Speech Therapy; 2. *Speech‐Language Pathology; 3. Apraxias [*therapy]; 4. Speech Disorders [*therapy];
MESH terms:
Neuromuscular electrostimulation for adults with chronic obstructive pulmonary disease
1. *Electric Stimulation Therapy; 2. Combined Modality Therapy [methods]; 3. Exercise Therapy [methods]; 4. Exercise Tolerance; 5. Muscle Strength [physiology]; 6. Pulmonary Disease, Chronic Obstructive [*therapy]; 7. Quadriceps Muscle [physiology]; 8. Quality of Life; 9. Randomized Controlled Trials as Topic;
MESH terms:
Mirtazapine adjunct for people with schizophrenia
1. *Schizophrenic Psychology; 2. Antidepressive Agents, Tricyclic [adverse effects, *therapeutic use]; 3. Antipsychotic Agents [*therapeutic use]; 4. Chemotherapy, Adjuvant; 5. Mianserin [adverse effects, *analogs & derivatives, therapeutic use]; 6. Mirtazapine; 7. Patient Dropouts [statistics & numerical data]; 8. Quality of Life; 9. Randomized Controlled Trials as Topic; 10. Schizophrenia [*drug therapy]; 11. Weight Gain;
MESH terms:
Educational interventions for improving primary caregiver complementary feeding practices for children aged 24 months and under
1. *Infant Nutritional Physiological Phenomena; 2. Breast Feeding [statistics & numerical data]; 3. Caregivers [*education]; 4. Child Development; 5. Food; 6. Randomized Controlled Trials as Topic; 7. Weaning;
MESH terms:
Trihexyphenidyl for dystonia in cerebral palsy
1. Anti‐Dyskinesia Agents [*therapeutic use]; 2. Cerebral Palsy [*complications]; 3. Dystonia [*drug therapy, etiology]; 4. Trihexyphenidyl [*therapeutic use];
MESH terms:
Cyclamen europaeum extract for acute sinusitis
1. Acute Disease; 2. Anti-Inflammatory Agents [*therapeutic use]; 3. Cyclamen [*chemistry]; 4. Nasal Polyps [drug therapy]; 5. Plant Extracts [adverse effects, *therapeutic use]; 6. Randomized Controlled Trials as Topic; 7. Rhinitis [drug therapy]; 8. Sinusitis [*drug therapy];
MESH terms:
Grommets (ventilation tubes) for recurrent acute otitis media in children
1. *Middle Ear Ventilation [adverse effects]; 2. Acute Disease; 3. Adenoidectomy; 4. Anti‐Bacterial Agents [therapeutic use]; 5. Otitis Media with Effusion [*therapy]; 6. Quality of Life; 7. Randomized Controlled Trials as Topic; 8. Recurrence; 9. Time Factors;
MESH terms:
Early intensive behavioral intervention (EIBI) for young children with autism spectrum disorders (ASD)
1. Behavior Therapy [*methods]; 2. Child Development Disorders, Pervasive [*therapy]; 3. Communication; 4. Controlled Clinical Trials as Topic; 5. Early Intervention, Educational [*methods]; 6. Early Medical Intervention [*methods]; 7. Intelligence;
MESH terms:
Lower versus higher oxygen concentrations titrated to target oxygen saturations during resuscitation of preterm infants at birth
1. *Resuscitation [adverse effects, methods]; 2. Cerebral Hemorrhage [epidemiology]; 3. Enterocolitis, Necrotizing [epidemiology]; 4. Infant Mortality; 5. Infant, Premature [*blood]; 6. Intubation, Intratracheal [statistics & numerical data]; 7. Lung Diseases [epidemiology]; 8. Neurodevelopmental Disorders [epidemiology, etiology]; 9. Oxygen [*administration & dosage, *analysis]; 10. Randomized Controlled Trials as Topic; 11. Retinopathy of Prematurity [epidemiology];
MESH terms:
Cyclodestructive procedures for non‐refractory glaucoma
1. Glaucoma, Open‐Angle [drug therapy, *surgery]; 2. Intraocular Pressure [radiation effects]; 3. Laser Coagulation [adverse effects, *methods];
MESH terms:
Smectite for acute infectious diarrhoea in children
1. Acute Disease; 2. Antidiarrheals [*therapeutic use]; 3. Diarrhea [*therapy, virology]; 4. Randomized Controlled Trials as Topic; 5. Rotavirus Infections [*complications]; 6. Silicates [*therapeutic use];
MESH terms:
Interventions for infantile haemangiomas of the skin
1. Adrenal Cortex Hormones [adverse effects, therapeutic use]; 2. Adrenergic beta‐Antagonists [administration & dosage]; 3. Antineoplastic Agents [therapeutic use]; 4. Bleomycin [therapeutic use]; 5. Hemangioma, Capillary [*therapy]; 6. Lasers, Dye [therapeutic use]; 7. Methylprednisolone [adverse effects, therapeutic use]; 8. Photochemotherapy [methods]; 9. Prednisolone [adverse effects, therapeutic use]; 10. Propranolol [administration & dosage]; 11. Radiotherapy [methods]; 12. Randomized Controlled Trials as Topic; 13. Remission Induction [methods]; 14. Skin Neoplasms [*therapy]; 15. Timolol [administration & dosage];